Year: 2026
Type: article
Abstract: Patient-reported outcomes can provide valuable evidence on the efficacy and tolerability of treatments throughout the drug development pipeline supporting regulatory decision-making, reimbursement and patient-centred care. Use of international guidelines and tools can optimise assessment and data quality and maximise impact. Calvert et al. highlight how patient-reported outcomes (PROs) provide critical evidence for drug regulation, reimbursement, and clinical care. They advocate for using international guidelines and tools to enhance data quality and maximize the impact of these data to support decision-making and patient-centred care.
Source: Communications Medicine
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: gold
Estimated APC paid: $3,690
Funders: Pfizer, Gilead Sciences, Sarcoma UK, Merck KGaA, Macmillan Cancer Support, LifeArc, University Hospitals Birmingham NHS Foundation Trust, UK Research and Innovation, Anthony Nolan, National Institute for Health and Care Research, Surgical Reconstruction and Microbiology Research Centre, European Regional Development Fund, Birmingham Biomedical Research Centre, National Institute for Health Research Applied Research Collaboration West, UCB Pharma
OpenAlex ID: W7161624652